Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Leading nanomedicine firm Nanobiotix successfully closes its $ 11 million series-C financing round

Abstract:
Nanobiotix, based in Paris, France, announces the closing of a $ 11 million series-C financing round. The company develops innovative therapeutic products for cancer using nanotechnologies.

Leading nanomedicine firm Nanobiotix successfully closes its $ 11 million series-C financing round

Paris | Posted on May 3rd, 2010

Nanobiotix raised US 11 million from a strong new and existing syndicate of investors. CIC Vizille Capital Innovation has led this new round with Masseran Gestion. Existing shareholder have strongly participated in the round, Matignon Technologies, OTC Asset Management, Cap Decisif Management, and Amorçage Rhône-Alpes.

"This successful closing is the recognition of the value of Nanobiotix breakthrough technology NanoXray. This financing will enable us to continue to advance our lead programs through clinical studies. We first plan on reinforcing our scientific /developpement team and resources: we are entering our first-in-man clinical study of nanoXray therapeutics with IGR Institut Gustave Roussy, - a Europe leading cancer treatment center - for Soft Tissue Sarcoma as initial indication. First preclinical data are very promising: safety in animals of NBTXR3 - when activated by ionizing radiation has been demonstrated; performance has clearly shown the potential of this product to become a new approach for cancer treatment," says Dr Laurent Levy, PhD, co-founder and CEO of Nanobiotix, a worldwide pioneer in nanomedicine.

"We are thrilled to be part of this very exciting adventure and pleased to help accelerate the development of a new class of cancer treatment, more effective and less deadly to healthy tissues. Nanobiotix has mastered the critical issues related to NanoXray reproductibility, scalability and stability," says Karine Lignel; CIC - Vizille Capital Innovation.

Since its creation in 2003, the company has made tremendous progresses and obtained significant results. It has a well balanced pipeline and a unique nanomedicine expertise in developing a very promising therapy for cancer treatment.

"We are confident in the development of Nanobiotix and its technology. We truly believe that is the best risk reward products in biotech field," says Jerome Snollaerts; Cap Decisif Management.

In parallel to the ongoing clinical developments, Nanobiotix has built an industrial and academic collaborative projects portfolio including research programs and industrial partnering, like Sonodrug with Philips Research or Biotech Corp in Malaysia.

"This is a significant step to the development of nanoXRay and we are excited to be that close to offer a potential alternative to patients," Patrick Langlois; Chairman of the non executive board.

####

About Nanobiotix
Nanobiotix is a leading nanomedicine company combining dramatic advances in nanotechnology and molecular biology to develop "nanoXray” a technology platform that is expected to be turned 'on' and 'off' outside the body to selectively treat a variety of cancers safely and noninvasively. Use of nanoXray is intended to resolve radiation therapy's biggest drawback: destruction of healthy tissue and its subsequent deleterious side effects when a high dose of Xray is necessary. After nanoXray nanoparticles accumulate in the target tissues, a standard X-ray is applied that is intended to generate a local therapeutic effect, designed to destroy only the targeted tumor cells. This mechanism suggests total control of the intended therapeutic effect.

About NanoXray Platform
NanoXray therapeutic platform is designed to enable the precise destruction of cancer cells made possible by the controlled application of an outside the body energy source, in that case an X-ray. The nanoparticles that comprise the nanoXray platform allow for an extensive combination of therapeutic modalities and malignant pathologies. Nbtxr3, the first product to be developed from the nanoXray pipeline, also is the first-in-class product to be activated by radiotherapy. The intended initial indications for Nbtxr3 are:

Soft Tissue Sarcoma - Hepatic Cancer - Colon cancer - Lung cancer - Pancreatic cancer

Dr Laurent Levy will be attending BIO Chicago, from May 3 to May 6.

For more information, please click here

Contacts:
60 rue de Wattignies
Bat B 3rd floor
75012 Paris, France

Tel : + 33 (0) 1 40 26 04 70
Fax : +33 (0) 1 40 26 04 44

Copyright © Business Wire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Possible Futures

GS7 Graphene Sensor maybe Solution in Fight Against Cancer January 25th, 2015

Nanotechnology in Energy Applications Market Research Report 2014-2018: Radiant Insights, Inc January 15th, 2015

'Mind the gap' between atomically thin materials December 23rd, 2014

A novel method for identifying the body’s ‘noisiest’ networks November 19th, 2014

Investments/IPO's/Splits

Malaysian Nanotechnology Company Nanopac Innovation Ltd. lists on the NSX January 19th, 2015

Aspen Aerogels, Inc. to Present at the Needham Growth Conference January 8th, 2015

Blend Therapeutics Secures $21 Million Financing and Unveils Novel Pentarin™ Platform for Cancer Therapeutics: Company’s Technology and Expertise in Cancer R&D Evolve to Create New Class of Miniaturized Biologic Drug Conjugates (mBDCs) Encapsulated in Nanoparticles January 8th, 2015

Nanometrics to Announce Fourth Quarter and Full Year Financial Results on February 2, 2015 January 7th, 2015

Nanomedicine

Teijin to Participate in Nano Tech 2015 January 22nd, 2015

2nd International Conference on Infectious Diseases & Nanomedicine (December 15-18, 2015, Kathmandu, NEPAL) January 22nd, 2015

Anti-microbial coatings with a long-term effect for surfaces – presentation at nano tech 2015 in Japan January 21st, 2015

A spoonful of sugar in silver nanoparticles to regulate their toxicity January 21st, 2015

Announcements

GS7 Graphene Sensor maybe Solution in Fight Against Cancer January 25th, 2015

Toyocolor to Launch New Carbon Nanotube Materials at nano tech 2015 January 24th, 2015

NANOPOSTER 2015 - 5th Virtual Nanotechnology Conference - call for abstracts January 24th, 2015

Nanosensor Used for Simultaneous Determination of Effective Tea Components January 24th, 2015

Nanobiotechnology

DNA 'glue' could someday be used to build tissues, organs January 14th, 2015

Photonic crystal nanolaser biosensor simplifies DNA detection: New device offers a simpler and potentially less expensive way to detect DNA and other biomolecules through changes in surface charge density or solution pH January 13th, 2015

Determination of Critical Force, Time for Manipulation of Biological Nanoparticles January 7th, 2015

DNA Origami Could Lead to Nano “Transformers” for Biomedical Applications: Tiny hinges and pistons hint at possible complexity of future nano-robots January 5th, 2015

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2015 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE